Extended Adjuvant AIs: Safe and Active, but Not Much Good

Paul E. Goss, MD, PhD, presented the 6.3-year analysis of the MA.17R breast cancer trial at the 2016 annual meeting of the American Society of Clinical Oncology (ASCO). He and his colleagues also published their results in The New England Journal of Medicine.¹ They sought to define the benefits of prolonging treatment with an adjuvant aromatase inhibitor (AI) beyond 5 years. More than 71% of the 1,918 women participating in the trial